6
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      “Toxic erythema” and eosinophilia associated to tocilizumab therapy in a COVID‐19 patient

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Since the new fatal pneumonia was identified in December 2019 in Wuhan, China, the WHO declared the infection a health emergency of international concern.

          The novel ss‐RNA ß‐coronavirus (SARS‐CoV‐2) spreads through airborne and direct contagion; virulence is high in the elderly and in patients with diabetes, chronic pulmonary, cardiovascular and neoplastic diseases. SARS‐CoV‐2 ssRNA is recognized by intracellular Pattern Recognition Receptors (PRRs), which trigger NF‐kB – the master regulator of inflammation – and Interferon Regulatory Factors (IRFs) 1.

          Related collections

          Author and article information

          Contributors
          teresa.grieco@uniroma1.it
          Journal
          J Eur Acad Dermatol Venereol
          J Eur Acad Dermatol Venereol
          10.1111/(ISSN)1468-3083
          JDV
          Journal of the European Academy of Dermatology and Venereology
          John Wiley and Sons Inc. (Hoboken )
          0926-9959
          1468-3083
          09 May 2020
          : 10.1111/jdv.16620
          Affiliations
          [ 1 ] Dermatology Unit Sapienza University of Rome Rome Italy
          [ 2 ] Infectious Disease Unit Sapienza University of Rome Rome Italy
          Author notes
          [*] [* ] Corresponding author

          Teresa Grieco, Dermatology Unit, La Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy

          Email: teresa.grieco@ 123456uniroma1.it

          Article
          JDV16620
          10.1111/jdv.16620
          7272956
          32386438
          4647e7f2-29ee-4401-bec6-c262dbcb82d2
          This article is protected by copyright. All rights reserved.

          This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

          History
          Page count
          Figures: 0, Tables: 0, Pages: 6, Words: 156
          Categories
          Letter to Editor
          Letters to Editor
          Custom metadata
          2.0
          accepted-manuscript
          Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.3 mode:remove_FC converted:05.06.2020

          Dermatology
          covid‐19,tocilizumab,eosinophilia,drug eruption
          Dermatology
          covid‐19, tocilizumab, eosinophilia, drug eruption

          Comments

          Comment on this article